GlassScriptPhysician profile
Cindy Jean Condray
NPI 1932675162
$858.23
in general payments reported to CMS, 2019-2025
16 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.32 · 2022: $187 · 2023: $215 · 2024: $215 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $155.55 | 2023-2025 | |
| Novo Nordisk INC | $142.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $77.04 | 2022-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $75.09 | 2022-2023 | Breztri |
| Abbvie INC. | $75.07 | 2022-2024 | |
| Amgen INC. | $62.87 | 2023-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $48.51 | 2021-2025 | Bexsero, Shingrix, Penmenvy |
| Merck Sharp & Dohme LLC | $36.02 | 2023 | Dificid, Zerbaxa |
| Dexcom, INC. | $34.96 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Myriad Genetic Laboratories, INC. | $32.12 | 2024 | Myrisk |
| Exact Sciences Corporation | $29.58 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $21.40 | 2022 | |
| Kyowa Kirin, INC. | $21.08 | 2025 | |
| Dynavax Technologies Corporation | $18.59 | 2025 | Heplisav-B |
| Boston Scientific Corporation | $14.62 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $13.73 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Condray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.